Re: Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer. M. R. Smith, R. A. Morton, K. G. Barnette, P. R. Sieber, S. B. Malkowicz, D. Rodriguez, M. L. Hancock and M. S. Steiner. J Urol 2010;184:1316-1321

J Urol. 2011 Jun;185(6):2430-1; author reply 2431-2. doi: 10.1016/j.juro.2011.02.036. Epub 2011 Apr 22.
No abstract available

Publication types

  • Comment
  • Letter

MeSH terms

  • Bone Density Conservation Agents / therapeutic use*
  • Fractures, Bone / chemically induced*
  • Fractures, Bone / prevention & control*
  • Gonadotropin-Releasing Hormone / agonists
  • Humans
  • Male
  • Prostatic Neoplasms / drug therapy*
  • Risk Factors
  • Toremifene / therapeutic use*

Substances

  • Bone Density Conservation Agents
  • Gonadotropin-Releasing Hormone
  • Toremifene